Insight, analysis & opinion from Joe Paduda

Jan
18

How to make negotiating drug prices pay off

Despite what some Congressional Dems say, requiring CMS Secretary Mike Leavitt to negotiate drug prices with big pharma is not going to save us gazillions of dollars.
It also won’t lead to a sudden decline in pharmaceutical research (sorry, Manhattan Institute). It’s good political theater, but the real impact will be minimal.
Unless…

Continue reading How to make negotiating drug prices pay off


Jan
16

A doc’s not happy about Fentora

In response to my post on new narcotic Fentora, which was picked up by Kevin, M.D. over at his blog, a physician reads the riot act to a commenter who said that docs should be blamed for any misuse.


Jan
16

Drug price negotiation and lousy research

Pundits and experts on the right side of the political spectrum are claiming that giving CMS the authority to negotiate drug prices will cost Americans $500 billion in lost productivity due to an annual loss of five million life years.
There are so many flaws in their arguments it’s hard to know where to start, but let’s plunge in.

Continue reading Drug price negotiation and lousy research


Joe Paduda is the principal of Health Strategy Associates

SUBSCRIBE BY EMAIL

SEARCH THIS SITE

A national consulting firm specializing in managed care for workers’ compensation, group health and auto, and health care cost containment. We serve insurers, employers and health care providers.

 

DISCLAIMER

© Joe Paduda 2024. We encourage links to any material on this page. Fair use excerpts of material written by Joe Paduda may be used with attribution to Joe Paduda, Managed Care Matters.

Note: Some material on this page may be excerpted from other sources. In such cases, copyright is retained by the respective authors of those sources.

ARCHIVES

Archives